JP2020531537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531537A5 JP2020531537A5 JP2020511441A JP2020511441A JP2020531537A5 JP 2020531537 A5 JP2020531537 A5 JP 2020531537A5 JP 2020511441 A JP2020511441 A JP 2020511441A JP 2020511441 A JP2020511441 A JP 2020511441A JP 2020531537 A5 JP2020531537 A5 JP 2020531537A5
- Authority
- JP
- Japan
- Prior art keywords
- canakinumab
- dose
- months
- events
- recurrent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000002526 effect on cardiovascular system Effects 0.000 claims 16
- 229960001838 canakinumab Drugs 0.000 claims 15
- 208000010125 myocardial infarction Diseases 0.000 claims 10
- 108010074051 C-Reactive Protein Proteins 0.000 claims 9
- 230000000306 recurrent effect Effects 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 102100032752 C-reactive protein Human genes 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 230000000250 revascularization Effects 0.000 claims 2
- 238000011272 standard treatment Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549971P | 2017-08-25 | 2017-08-25 | |
| US62/549,971 | 2017-08-25 | ||
| US201762584380P | 2017-11-10 | 2017-11-10 | |
| US62/584,380 | 2017-11-10 | ||
| PCT/IB2018/056468 WO2019038740A1 (en) | 2017-08-25 | 2018-08-24 | USE OF CANAKINUMAB |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531537A JP2020531537A (ja) | 2020-11-05 |
| JP2020531537A5 true JP2020531537A5 (cg-RX-API-DMAC7.html) | 2021-09-09 |
Family
ID=63643018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511441A Withdrawn JP2020531537A (ja) | 2017-08-25 | 2018-08-24 | カナキヌマブの使用 |
| JP2020511450A Withdrawn JP2020531539A (ja) | 2017-08-25 | 2018-08-24 | カナキヌマブの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511450A Withdrawn JP2020531539A (ja) | 2017-08-25 | 2018-08-24 | カナキヌマブの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20200239564A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3710476A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020531537A (cg-RX-API-DMAC7.html) |
| TW (2) | TW201919695A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2019038740A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202008718UA (en) * | 2018-03-09 | 2020-10-29 | Brigham & Womens Hospital Inc | Combination therapy for cardiovascular diseases |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| CN113491820A (zh) * | 2021-07-30 | 2021-10-12 | 复旦大学附属中山医院 | 涂层Canakinumab的药物球囊的制备及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| AU2012316083A1 (en) | 2011-09-30 | 2014-04-17 | Novartis Ag | Use of IL-1 beta binding antibodies |
-
2018
- 2018-08-24 US US16/641,889 patent/US20200239564A1/en not_active Abandoned
- 2018-08-24 JP JP2020511441A patent/JP2020531537A/ja not_active Withdrawn
- 2018-08-24 WO PCT/IB2018/056468 patent/WO2019038740A1/en not_active Ceased
- 2018-08-24 EP EP18773836.4A patent/EP3710476A1/en not_active Withdrawn
- 2018-08-24 TW TW107129672A patent/TW201919695A/zh unknown
- 2018-08-24 EP EP18773257.3A patent/EP3710475A1/en not_active Withdrawn
- 2018-08-24 WO PCT/IB2018/056465 patent/WO2019038737A1/en not_active Ceased
- 2018-08-24 US US16/641,897 patent/US20200199220A1/en not_active Abandoned
- 2018-08-24 JP JP2020511450A patent/JP2020531539A/ja not_active Withdrawn
- 2018-08-27 TW TW107129849A patent/TW201919696A/zh unknown
-
2023
- 2023-03-21 US US18/187,242 patent/US20240043525A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Suzuki et al. | Skeletal muscle wasting in chronic heart failure | |
| Lake | The fat of the matter: obesity and visceral adiposity in treated HIV infection | |
| Cannon et al. | Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study | |
| JP2020531537A5 (cg-RX-API-DMAC7.html) | ||
| Hawkey et al. | Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors | |
| Chan et al. | Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis | |
| JP2019514925A5 (cg-RX-API-DMAC7.html) | ||
| Abeles et al. | Gout and cardiovascular disease: crystallized confusion | |
| HRP20221150T1 (hr) | Semaglutid u kardiovaskularnim stanjima | |
| JP2020531539A5 (cg-RX-API-DMAC7.html) | ||
| Wong et al. | Cardiovascular issues of COX-2 inhibitors and NSAIDs | |
| Badings et al. | Early or late intervention in patients with transient ST‐segment elevation acute coronary syndrome: subgroup analysis of the ELISA‐3 trial | |
| Priti et al. | High versus low dose statin therapy in Indian patients with acute ST-segment elevation myocardial infarction undergoing thrombolysis | |
| JP2019501226A5 (cg-RX-API-DMAC7.html) | ||
| Athyros et al. | Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? | |
| JP2021502379A5 (cg-RX-API-DMAC7.html) | ||
| IS6553A (is) | Kvarnaðar agnir með duldu bragði | |
| Sunpath et al. | Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa | |
| Chia et al. | Beta‐blocker, angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker, nitrate‐hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID 2): an evidence‐based mnemonic for the treatment of systolic heart failure | |
| WO2019016673A3 (en) | STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB | |
| Li et al. | Efficacy and Safety of Standard‐Dose Versus Half‐Dose Tirofiban in Patients with Non‐ST Elevation Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention | |
| Elgendy et al. | Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure | |
| Dennert et al. | Giant cell myocarditis triggered by a parvovirus B19 infection | |
| Neogi et al. | Pursuit of a dual-benefit antigout drug: a first look at arhalofenate | |
| Perez-Ruiz et al. | FRI0370 Efficacy and safety of lesinurad (RDEA594), a novel URAT1 inhibitor, in combination with allopurinol in allopurinol-refractory gout patients: Results from a randomized, blinded, placebo-controlled, phase 2b extension study |